> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Day One Bio Granted Pediatric Voucher
- URL: https://www.fdaweb.com/day-one-bio-granted-pediatric-voucher/
- Published: 2024-05-14T12:00:00.000Z
- Updated: 2026-09-14T14:30:46.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5156974

*Federal Register* notice: FDA is announcing that it issued Day One Biopharmaceuticals a priority review voucher for its recently approved pediatric disease product application. The agency determined that the company’s Ojemda (tovorafenib), approved 4/23 for treating certain patients six months of age and older with relapsed or refractory pediatric low-grade glioma, meets the criteria for a priority review voucher. To view the notice, click [here](https://www.accessdata.fda.gov/drugsatfda%5Fdocs/label/2024/218033s000lbl.pdf?ref=fdaweb.com).